Last reviewed · How we verify
AEZS-108 / zoptarelin doxorubicin
AEZS-108 is a conjugate of a GnRH agonist (zoptarelin) linked to the chemotherapy drug doxorubicin, designed to deliver cytotoxic payload selectively to GnRH receptor-expressing cancer cells.
AEZS-108 is a conjugate of a GnRH agonist (zoptarelin) linked to the chemotherapy drug doxorubicin, designed to deliver cytotoxic payload selectively to GnRH receptor-expressing cancer cells. Used for Ovarian cancer, Endometrial cancer.
At a glance
| Generic name | AEZS-108 / zoptarelin doxorubicin |
|---|---|
| Also known as | AEZS-108 |
| Sponsor | AEterna Zentaris |
| Drug class | Targeted chemotherapy conjugate / GnRH receptor-targeted cytotoxic |
| Target | GnRH receptor (GnRHR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The zoptarelin moiety binds to GnRH receptors that are overexpressed on certain cancer cells, particularly ovarian and endometrial cancers. Upon receptor-mediated internalization, the doxorubicin payload is released intracellularly, allowing targeted chemotherapy delivery while potentially reducing systemic toxicity compared to free doxorubicin.
Approved indications
- Ovarian cancer
- Endometrial cancer
Common side effects
- Nausea and vomiting
- Myelosuppression
- Fatigue
- Cardiotoxicity
- Alopecia
Key clinical trials
- Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer (PHASE3)
- Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AEZS-108 / zoptarelin doxorubicin CI brief — competitive landscape report
- AEZS-108 / zoptarelin doxorubicin updates RSS · CI watch RSS
- AEterna Zentaris portfolio CI